01
Cash & equivalents increased 66.6%
Cash & equivalents changed +66.6% from the comparable as-filed period.
$43.4M→$72.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTEdgewise Therapeutics, Inc.'s latest supported as-filed period reports net income of -$57.3M, 58.7% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +66.6% from the comparable as-filed period.
Net income changed -58.7% from the comparable as-filed period.
Operating income changed -45.4% from the comparable as-filed period.
Research & development changed +41.7% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
EWTX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001705477-26-000002SEC ↗4/AAug 17, 2026Period Aug 12, 20260001644087-26-000006SEC ↗4/AAug 17, 2026Period Aug 12, 20260001853529-26-000003SEC ↗4/AAug 17, 2026Period Aug 12, 20260001191702-26-000002SEC ↗4/AAug 17, 2026Period Aug 12, 20260001853109-26-000002SEC ↗4Aug 14, 2026Period Aug 12, 20260001705477-26-000001SEC ↗4Aug 14, 2026Period Aug 12, 20260001644087-26-000005SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 12, 2026Filed Aug 17, 2026 | Nofi MichaelChief Financial Officer | Grant Or AwardDirect · amended | 48,750 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Stock-based compensation changed +21.1% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001853529-26-000002